Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.
Presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum included a 10-year follow-up of patients after mitoxantrone treatment, a comparison of no evidence of disease activity in patients treated with ocrelizumab or IFN Î²-1a, and an evaluation of no evidence of progression in a trial of patients administered ocrelizumab or placebo.
Clinical Follow-up of 411 Patients with Multiple Sclerosis Ten Years after Mitoxantrone Treatment Abstract link.
Mitoxantrone offered patients a sustained (albeit reduced at 5 years) effect at 10 years; treatment was more likely to benefit less active and disabled relapsing patients.
NEDA Analysis by Epoch in Patients with Relapsing Multiple Sclerosis Treated with Ocrelizumab: Results from the OPERA I and OPERA II Phase III Studies Abstract link.
How many patients with relapsing MS had no evidence of disease activity (NEDA) on ocrelizumab vs interferon beta 1-a (IFN Î²-1a)?
Evaluation of No Evidence of Progression (NEP) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial Abstract link.